Most explanations of the Spravato REMS treat it as paperwork, a form to submit before you can order the drug. That framing gets clinics into trouble, because the enrollment form is the smallest part of it. The REMS sets requirements on who must be in the building, what equipment must be on site, what you document after every single dose, and how long each patient occupies a chair. Those requirements decide how many patients your program can hold.
This is what the program actually requires, where each requirement comes from, and what it does to your capacity once you are running.
Getting the setting certified
Certification happens at the level of the healthcare setting, not the individual prescriber, and outpatient settings certify on a different form from inpatient ones. Emergency departments certify through inpatient enrollment.
The enrollment sequence itself is short. Designate an Authorized Representative to oversee implementation and compliance on behalf of the setting. Have that representative review the SPRAVATO prescribing information and the REMS Program Overview. Then complete and submit the Outpatient Healthcare Setting Enrollment Form.
What the form does not tell you is that submitting it commits you to a standing set of operational obligations. The ones that shape a clinic day are these.
A prescriber must be on site during administration and throughout the monitoring period. This is a federal REMS requirement, not a state scope-of-practice question, and it is the single biggest constraint on when you can run sessions.
A pulse oximeter must be available on site. Monitoring is not just blood pressure.
All relevant staff must be trained and you need documented processes covering dispensing, administration, monitoring and the REMS paperwork.
A Patient Monitoring Form goes to the REMS for every patient within seven days of every dose. Not every course. Every dose. For a patient in twice-weekly induction that is two forms a week, and it is the requirement most likely to slip once the schedule gets busy.
Certification is quick. Being ready to dose is not, and the gap between the two is where new programs get caught.
Enrolling patients
Patients treated in outpatient settings, meaning medical offices and clinics, must be enrolled in the program. This is a separate obligation from certifying the setting, and it is per patient.
Enrollment needs to happen before the first dose rather than alongside it, so it belongs in your intake workflow and not in the treatment room.
If a patient moves between certified settings, the REMS must be notified in advance. That is easy to miss when a patient transfers in mid-course and everyone assumes the paperwork travelled with them.
What the monitoring requirement actually says
This is the part worth reading precisely, because it is where the operational cost sits and where paraphrase causes problems.
Spravato is administered by the patient under the direct observation of a healthcare provider, and patients are monitored for at least two hours after administration and until sedation, dissociation and respiratory depression have resolved. Pulse oximetry is part of that monitoring. The drug is dispensed and administered in certified healthcare settings only, and must never be dispensed directly to a patient for home use.
Blood pressure has its own schedule. Assess it before dosing. Reassess at approximately 40 minutes after dosing, which corresponds with peak concentration, and subsequently as clinically warranted.
Discharge is a clinical judgment against a floor, not a timer. The label’s criterion is that if blood pressure is decreasing and the patient appears clinically stable for at least two hours, the patient may be discharged at the end of the post-dose monitoring period. Note that the test is decreasing, not normalized: a patient whose pressure is still somewhat elevated but falling, who is otherwise stable and whose sedation and dissociation have resolved, can go home. A patient whose pressure is climbing at two hours cannot. “Safe to leave” is the actual standard.
The consequence for scheduling is that a Spravato session is not a two-hour block. It is check-in, pre-dose assessment, administration, at least two hours of monitored observation with a blood pressure check at 40 minutes, a discharge assessment that may extend it, and a monitoring form to file within the week. Clinics that book them as two-hour slots run late by the middle of the morning.
The pharmacy side
Pharmacies must be certified in the REMS as well, and may only dispense Spravato to healthcare settings that are themselves certified. This closes the loop: certified pharmacy to certified setting to observed administration, with no path to a patient’s home at any point.
It also means your supply is only as reliable as your pharmacy’s certification status, which is worth confirming rather than assuming, particularly if you are switching suppliers or opening a second location.
What has actually changed, and what has not
“Spravato REMS changes” is a search a lot of clinic managers run when they hear a rumour, so it is worth being plain about this.
The REMS has been modified three times in 2026. In January the FDA approved a modification reverting vendor-related changes to the REMS program website. In April it approved the addition of Spanish translations of REMS materials. In June it approved updated website workflows, and the current REMS document carries that date.
All three were administrative. None touched setting certification, patient enrollment, the prescriber-on-site requirement, or the two-hour monitoring period, and each reconfirms that the timetable for REMS assessments remains the one approved on March 5, 2019. If someone tells you the monitoring period has been shortened or the REMS withdrawn, ask them for the citation.
The change worth knowing about is older and sits in the label rather than the REMS. In January 2025 the FDA approved Spravato as monotherapy for treatment-resistant depression, so it is now indicated for TRD in adults either alone or alongside an oral antidepressant, and separately for depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior, in conjunction with an oral antidepressant. Monotherapy widens who is eligible. It changes nothing about what you have to do once they are in the chair.
What REMS does to your capacity
Here is the part that rarely gets written down, and the reason we care about it as a marketing problem.
The dosing schedule for treatment-resistant depression runs twice per week for weeks one to four, once weekly for weeks five to eight, then every two weeks or once weekly from week nine, individualized to maintain response. Every one of those sessions carries the full monitoring requirement and a prescriber on site.
Work it through with round numbers. Say you have two monitored recliners and a nine-hour clinical day. Allowing for the observation period plus turnover, that is realistically three sessions per chair per day, so six session-slots a day and thirty a week.
A patient in induction consumes two of those slots every week. A weekly maintenance patient consumes one. A biweekly patient consumes half of one. Thirty slots does not mean thirty patients. If your panel were entirely in induction it would mean fifteen, and no real clinic has that mix.
Those numbers are illustrative and yours will differ, but three things follow whatever your inputs are. Your ceiling is set by monitored chair-hours and prescriber coverage, not by demand, and no amount of marketing moves it. The mix matters more than the headcount, because induction patients cost two slots each and are the ones most likely to drop out early, leaving a chair blocked for a course that stopped in week two. And prescriber availability, not chair count, is often the real bottleneck, because a room full of recliners is worth nothing on an afternoon when nobody who can prescribe is in the building.
We have written about the same arithmetic on the TMS side in TMS chair utilization, and about why consults fail to convert into started courses in why your consult leads don’t book. Spravato has the same shape with a tighter monitoring requirement.
The practical implication is that a Spravato program does not need more inquiries in the abstract. It needs the right number of the right patients arriving at a rate its monitored chairs and its prescriber cover can absorb, and it needs the ones who start to finish. A clinic marketing itself into a waitlist it cannot serve has made its problem worse.
Common questions
How long does Spravato REMS certification take?
The enrollment itself is quick: designate a representative, review the prescribing information and REMS Program Overview, submit the outpatient enrollment form. Plan instead around what comes after, which is pharmacy setup, staff training, getting a pulse oximeter and documented processes in place, and building a scheduling template that accounts for prescriber cover.
Do patients have to be enrolled individually?
Yes, for outpatient settings. Setting certification and patient enrollment are two separate requirements. If a patient moves to a different certified setting, the REMS must be notified in advance.
Can the two-hour monitoring period be shortened?
No. Two hours is a minimum. Discharge additionally requires that blood pressure is decreasing, that the patient appears clinically stable, and that sedation, dissociation and respiratory depression have resolved, so some sessions run longer.
Does a prescriber have to be present?
Yes. The REMS requires a prescriber on site during administration and throughout the monitoring period. This is a federal requirement and it applies regardless of what your state allows other staff to do.
What do we have to file after each dose?
A Patient Monitoring Form, submitted to the SPRAVATO REMS within seven days of each dose. Build it into the session workflow rather than leaving it to a weekly catch-up.
Can a patient take Spravato home?
No. It is dispensed and administered in certified healthcare settings only and must never be dispensed to a patient for home use. This is the requirement the whole REMS is built around.
Is there a generic esketamine?
No generic esketamine nasal spray is FDA-approved as of August 2026. If that changes, confirm the REMS position with your pharmacy rather than assuming it mirrors the brand.
Before you scale the program
The REMS is not conceptually hard. The requirements are clear once you have read the REMS document and the label rather than a summary of them.
What catches clinics is that those requirements set a hard ceiling on throughput, and most work out where their ceiling is by hitting it, usually around the point where induction patients and maintenance patients start competing for the same recliner on an afternoon when the prescriber is booked elsewhere. Knowing that number in advance changes what you build, how many chairs you commission, and how fast you should be filling them.
We are a marketing agency for mental health clinics, not a compliance consultancy. Everything above is drawn from the FDA REMS document and the prescribing information, both linked below, and your medical director should be the one who signs off on how it applies to your setting. If billing is the question rather than compliance, we covered the 2026 code change separately in Spravato CPT codes and billing.
What we can help with is the other half, which is whether the right patients are finding you and whether the ones who inquire actually start. That is what we do for Spravato clinics, and the growth audit is free.
Sources
Certification requirements, prescriber and pulse oximetry requirements, patient enrollment, transfer notification and the Patient Monitoring Form deadline from the FDA-approved SPRAVATO REMS document (June 2026) and the SPRAVATO REMS Program Overview. Monitoring, blood pressure, discharge criteria, indications and dosing from the SPRAVATO prescribing information. The 2026 REMS modifications from FDA supplement approval letters S-027, S-028 and S-029. Last reviewed August 2026.
